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PHARMACOGENETIC-ORIENTED WARFARIN THERAPY IN RUSSIA
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OBJECTIVES: To evaluate the potential clinical and economic outcomes of using
genotype data to guide the management of warfarin anticoagulation therapy.
METHODS: A decision tree was designed to simulate two groups – group of stan-
dard care and genotyped group. Both groups were separated by CYP2C9 genotypes
in patients with alleles CYP2C9*2 and CYP2C9*3 and patients with genotype
CYP2C9*1*1. CYP2C9*1*1 patients were subdivided further into VKORCBB and
VKORCAA/AB types. Outcomes in each group were: major bleeding (gastrointesti-
nal and intracranial), minor bleeding (hemorrhoid, hemarthrosis, hemophtalmos
and others) and no bleeding. Direct medical costs from the Russian healthcare
system point of view were estimated. Rate of bleedings in patients with different
genotypes and relative risks of bleedings in pharmacogenetic-oriented approach
were obtained from the literature. Sensitivity analysis to key parameters was
performed. RESULTS: In the basic scenario costs of the standard treatment were
higher than in pharmacogenetics-oriented group: 8545 rubles (USD305) and 6806
rubles (USD243) for 1 patient per year respectively. Sensitivity analysis showed that
the model is sensitive to the price of pharmacogenetic test only: the pharmacoge-
netic approach remains cost-saving until the test costs less than 2600 rubles
(USD93). CONCLUSIONS: In the Russian health care system, pharmacogenetic-
oriented warfarin therapy is cost saving if the price of pharmacogenetic test does
not exceed 2600 rubles (USD93).
PCV65
CLINICO-ECONOMIC EVALUATION OF COMPLEX CARDIOVASCULAR THERAPY
WITH MAGNESIUM OROTATE IN PATIENTS WITH CHRONIC HEART FAILURE
VERSUS STANDARD THERAPY IN UKRAINE
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OBJECTIVES: To evaluate the profitability of the complex cardiovascular therapy
with magnesium orotate in patients with chronic heart failure (CHF) IV functional
class (NYHA IV).METHODS:Cost-effectiveness evaluation of 2 treatment strategies
was performed using the modeling decision tree. Data from various sources: the
results of two clinical trials (Stepura O.B., Martynow A.I., 2009; Libis R.A. et al, 1999)
and National standard of treatment of patients with CHF FC IV were used in the
modeling. Cost-effectiveness ratio was evaluated in accordance with the threshold
willingness to pay for improving health achievement. The analysis of the impact of
the investigated treatment strategies on the budget, taking into account the lost
productivity was conducted. RESULTS: The inclusion of magnesium orotate in the
CHF standard therapy improves the health (NNT was 1 / 0, 24  4), it gives an
additional 0,14 QALYs and requires additional costs. Only direct medical costs were
included in the cost value. Incremental cost-effectiveness ratio was 1517,82 $ / add.
QALY. It is less than GDP per capita (current threshold willingness to pay), i.e.
cardiovascular therapy with magnesium orotate is cost effective. However, taking
into account the financial capacity of the health system in Ukraine, in real practice
such costs for achieve better health are less acceptable than the costs of standard
therapy. Indirect costs (lost productivity) during 2 years in the application of stan-
dard therapy with magnesium orotate were less than indirect costs in application
only standard therapy. Saving money - 606,7 $ per patient. CONCLUSIONS: Thus
the inclusion of magnesium orotate in the standard therapy in patients with CHF is
cost effective. High direct costs are compensated due in indirect costs savings.
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OBJECTIVES: Salt consumption in Hungary is high in international comparison, the
average salt intake is 17,28g per day in men and 12,05g in women. Our aim was to
study the cost-effectiveness of the salt intake reduction program run by the Hun-
garian National Institute for Food and Nutrition Science. METHODS: We built a
cohort simulation Markov-model. The health benefit achieved by reduced salt in-
take was calculated for the 40-60 year old Hungarian population in 7 health states:
healthy, hypertension, acute- and post AMI and stroke, death The transitional
probabilities were calculated from national and international publications. We
used the data of National Health Found and expert estimations to define the costs
of interventions and health states. The efficacy was modeled with the use of data
from the literature. It was assumed that 3g salt reduction results in 5Hgmm decline
in systolic blood pressure (SBP) and 1Hgmm SBP lowering will reduce the preva-
lence of the hypertension with 1%. A discount rate of 5% was applied. RESULTS: If
a public health program could reduce the salt intake to 10g/day/capita at in 5 years
by 31 USD PPP/capita/year investment, then the ICER would be 4090.5 USD PPP
(1USD PPP128.92 HUF). In this scenario the lifelong risk of AMI and stroke would
decrease with 0.0034The incremental cost of the intervention is 27.15 USD PPP, and
the QALY win is 0.0066. CONCLUSIONS: An effective public health program to
reduce salt intake would be cost-effective in Hungary.
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OBJECTIVES: To measure the comparative direct medical care costs between inci-
dent warfarin patients who did or did not experience genotyping to guide dosing.
METHODS: We reanalyzed the previously published MM-WES in which we dem-
onstrated that genotyping reduces the risk of hospitalization for bleeding and
thromboembolism in patients who initiate warfarin treatment in typical outpa-
tient practice settings. We used a cost consequence analysis to estimate the
6-month costs and consequences of warfarin genotyping. The intervention group
(IG) comprised 896 patients and a comparison group was constructed from 2688
historical controls (HC). The direct medical care costs were estimated for inpatient,
office visits and laboratory utilization (including cost of genotyping) and summed
to a total cost per patient. A boot-strapping method was performed to estimate
confidence limits around the difference in mean cost per patient to assess statis-
tical significance. RESULTS: Over the 6-month monitoring period, the all cause–
related per patient costs for the genotyped IG patient was $4127 compared to $5040
for HC. The all-cause difference of -$913 per patient reached statistical significance,
95% CI (-$895, -$930). Various subgroup analyses including warfarin-related costs
will be presented. CONCLUSIONS: Our analysis suggests that providing results of
warfarin genotyping to treating physicians in typical outpatient settings produces
cost-savings within six months of initiating warfarin therapy. These estimates are
likely conservative as they do not include ancillary costs such as rehabilitation or
indirect costs, nor do they estimate costs beyond six months.
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OBJECTIVES: According to current Dutch guidelines, antihypertensive treatment
for patients with mild hypertension is recommended if the 10-year fatal cardiovas-
cular disease (CVD) risk exceeds 10% or if accompanying risk factors are present.
Recent evidence suggests that lifelong CVD risk estimates might be more informa-
tive than 10-year risk estimates. The aim of this study was to estimate the eco-
nomic impact and influence on CVD risk of blood pressure (BP) reduction, in pa-
tients ineligible for treatment according to guidelines. METHODS: A Markov model
was developed to assess the lifetime costs and health benefits of BP reduction with
hydrochlorothiazide (HCT) or HCT plus losartan. Patients had mild hypertension
and low 10-year CVD risk. The SCORE risk estimates were modified to predict fatal
and non-fatal events over a lifelong time horizon. We analysed scenarios for dif-
ferent age groups, gender and reductions in BP. Costs and health effects were
discounted at 4.0% and 1.5%, respectively; a Dutch healthcare perspective was
used.RESULTS:A total of 48 different scenarios were modeled. Minor BP reductions
were potentially not cost-effective in young women treated with HCT (€59,000 per
life-year gained (LYG)), whereas potential cost-effectiveness was observed in a
comparable male population (€12,000 per LYG). BP reduction was, generally, found
to be more cost-effective in men, in older subjects and for larger BP reductions (up
to cost-saving results). Results for HCT plus losartan were comparable.
CONCLUSIONS: In patients ineligible for antihypertensive treatment according to
current Dutch guidelines, reducing BP, nonetheless, resulted in clinical benefits for
several patient populations. BP reduction was found to be potentially cost-effective
in males for all age groups and even cost-saving in older ages, whereas for females
it was less favorable. This, together with recent decreases in drug prices, should
trigger further discussion on antihypertensive treatment in patients with low 10-
year fatal CVD risk.
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OBJECTIVES: The PLATO trial showed that in patients with acute coronary syn-
dromes (ACS) treatment with ticagrelor plus acetylsalicylic acid (ASA) compared
with clopidogrel/ASA significantly reduced the rate of myocardial infarction (MI),
stroke, or death from vascular causes without a significant increase in the rate of
overall major bleedings. The present study evaluates the long-term cost-effective-
ness of treating patients with ticagrelor in Germany from the perspective of the
Statutory Health Insurance (SHI). METHODS: : A two-part decision-analytic model,
comprising a decision tree approach for the first year followed by a long-term
Markov model, was constructed to estimate lifetime costs and life year gained
(LYG) of treating ACS patients for one year with ticagrelor/ASA compared with
clopidogrel/ASA. Data for the first year were derived from the PLATO trial. For the
long-term model the German lifetable from the cause-of-death-statistics and se-
lected conservative assumptions were utilized to extrapolate survival conditional
on whether a non-fatal MI, a non-fatal stroke or no event occurred during the first
year. Costs were based on official tariffs (e.g. DRGs) and published literature. For the
base case daily cost of €2.99 was applied for ticagrelor. Daily cost for clopidogrel was
applied in a range from €0.38 (lowest generic) to €2.44 (Plavix) with an average
generic cost of €0.68 (base case). Extensive probabilistic, uni- and multivariate sen-
sitivity analyses were performed. RESULTS: : Treatment with ticagrelor was asso-
ciated with 0.16 LYG versus clopidogrel. The cost per LYG in the base case was
€3,361. Overall the cost per LYG ranged from €-430 (dominant situation) to €4,077
compared with clopidogrel (Plavix vs. lowest generic). Results were consistent
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